Cargando…

In Silico Mixed Ligand/Structure-Based Design of New CDK-1/PARP-1 Dual Inhibitors as Anti-Breast Cancer Agents

CDK-1 and PARP-1 play crucial roles in breast cancer progression. Compounds acting as CDK-1 and/or PARP-1 inhibitors can induct cell death in breast cancer with a selective synthetic lethality mechanism. A mixed treatment by means of CDK-1 and PARP-1 inhibitors resulted in radical breast cancer cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bono, Alessia, La Monica, Gabriele, Alamia, Federica, Mingoia, Francesco, Gentile, Carla, Peri, Daniele, Lauria, Antonino, Martorana, Annamaria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531453/ https://www.ncbi.nlm.nih.gov/pubmed/37762072 http://dx.doi.org/10.3390/ijms241813769

Ejemplares similares

In Silico Design of New Dual Inhibitors of SARS-CoV-2 M(PRO) through Ligand- and Structure-Based Methods
por: Bono, Alessia, et al.
Publicado: (2023)

Design and Synthesis of Novel Thieno[3,2-c]quinoline Compounds with Antiproliferative Activity on RET-Dependent Medullary Thyroid Cancer Cells
por: La Monica, Gabriele, et al.
Publicado: (2023)

Antiproliferative Activity Predictor: A New Reliable In Silico Tool for Drug Response Prediction against NCI60 Panel
por: Martorana, Annamaria, et al.
Publicado: (2022)

In Silico Identification of Small Molecules as New Cdc25 Inhibitors through the Correlation between Chemosensitivity and Protein Expression Pattern
por: Lauria, Antonino, et al.
Publicado: (2021)

Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors
por: Monica, Gabriele La, et al.
Publicado: (2021)

In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection
por: Martorana, Annamaria, et al.
Publicado: (2020)

Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure–Activity Relationship Insights and Evolution Perspectives
por: La Monica, Gabriele, et al.
Publicado: (2022)

Antiproliferative Properties and G-Quadruplex-Binding of Symmetrical Naphtho[1,2-b:8,7-b’]dithiophene Derivatives
por: Lauria, Antonino, et al.
Publicado: (2021)

Synthesis, biological evaluation, and in silico studies of novel chalcone- and pyrazoline-based 1,3,5-triazines as potential anticancer agents
por: Moreno, Leydi M., et al.
Publicado: (2020)

Quinoline-Based Molecules Targeting c-Met, EGF, and VEGF Receptors and the Proteins Involved in Related Carcinogenic Pathways
por: Martorana, Annamaria, et al.
Publicado: (2020)

Dual function of HPF1 in the modulation of PARP1 and PARP2 activities
por: Kurgina, Tatyana A., et al.
Publicado: (2021)

Synthesis of Novel Dual Target Inhibitors of CDK12 and PARP1 and Their Antitumor Activities in HER2-Positive Breast Cancers
por: Lin, Shanshan, et al.
Publicado: (2023)

COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION
por: Johnson, Neil, et al.
Publicado: (2011)

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition
por: Aziz, Diar, et al.
Publicado: (2021)

PARty promoters: Hormone-dependent gene regulation requires CDK2 activation of PARP1
por: Wright, Roni H.G., et al.
Publicado: (2012)

In Silico Investigation of Potential PARP-1 Inhibitors from Traditional Chinese Medicine
por: Chen, Kuan-Chung, et al.
Publicado: (2014)

Minor grove binding ligands disrupt PARP-1 activation pathways
por: Kirsanov, Kirill I., et al.
Publicado: (2014)

Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation
por: Quan, Chuntao, et al.
Publicado: (2023)

Dual Inhibitors of PARPs and ROCKs
por: Antolín, Albert A., et al.
Publicado: (2018)

Identification of an LPS-Induced Chemo-Attractive Peptide from Ciona robusta
por: Longo, Valeria, et al.
Publicado: (2020)

Design, synthesis and in silico studies of new quinazolinone derivatives as antitumor PARP-1 inhibitors
por: Ramadan, Sayed K., et al.
Publicado: (2020)

In Silico Investigation of the Molecular Mechanism of PARP1 Inhibition for the Treatment of BRCA-Deficient Cancers
por: Yan, Fengqin, et al.
Publicado: (2023)

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer
por: Konecny, Gottfried E.
Publicado: (2019)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
por: Maluchenko, Natalya, et al.
Publicado: (2022)

How ligands regulate the binding of PARP1 with DNA: Deciphering the mechanism at the molecular level
por: Wang, Kai, et al.
Publicado: (2023)

Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening
por: Elkamhawy, Ahmed, et al.
Publicado: (2021)

Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
por: Yélamos, José, et al.
Publicado: (2020)

In Silico Docking of HNF-1a Receptor Ligands
por: Sridhar, Gumpeny Ramachandra, et al.
Publicado: (2012)

Uncoupling of PARP1 Trapping and Inhibition Using Selective PARP1 Degradation
por: Wang, Shuai, et al.
Publicado: (2019)

Combination of ligand and structure based virtual screening approaches for the discovery of potential PARP1 inhibitors
por: Al-Sanea, Mohammad M., et al.
Publicado: (2022)

Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment
por: Chilà, Rosaria, et al.
Publicado: (2022)

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)

Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids
por: Cesari, Eleonora, et al.
Publicado: (2023)

Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines
por: Lukoseviciute, Monika, et al.
Publicado: (2023)

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
por: Pignochino, Ymera, et al.
Publicado: (2017)

In Silico Screening Identifies a Novel Potential PARP1 Inhibitor Targeting Synthetic Lethality in Cancer Treatment
por: Li, Jian, et al.
Publicado: (2016)

Discovery of novel anti-tumor compounds targeting PARP-1 with induction of autophagy through in silico and in vitro screening
por: Shi, Danfeng, et al.
Publicado: (2022)

A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer
por: Tian, Chenchen, et al.
Publicado: (2022)

The multifunctional protein YB-1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors
por: Alemasova, Elizaveta E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8te2v5q5d0u74he2q5h5504e0s